Adalvo announces the successful DCP approval for Ethinylestradiol/Drospirenone 0.03mg /3mg tablets.
Based on the reference brand Yasmin, Ethinylestradiol/Drospirenone has been developed in collaboration with one of our strategic partners. The INN is a low-dose oral contraceptive that generated approximately $826mio in global sales in 2023, according to IQVIA.
The DCP approval reinforces Adalvo's dedication to advancing women’s health through the development of cost-effective and accessible differentiated treatments.
Additionally, registrations for Ethinylestradiol/Drosperinone 0.02mg/3mg are currently ongoing, demonstrating Adalvo's commitment to providing a wide range of hormonal treatment options.
At Adalvo, there are no half-measures – we are always on target. When your mission is to be faster and stronger than your competitors, you need a winning team driving your vision forward.
Partner Up Now!